Intercept Pharmaceuticals (ICPT) Bullish Stance Reiterated at Needham & Company Following AASLD Meeting

Needham & Company analyst Alan Carr reiterated a Buy rating and $500 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following the AASLD meeting.

Carr commented, "Intercept presented additional data relating to the Phase 3 OCA POISE trial in PBC and hosted an event with investors at the AASLD meeting. This follows publication of Phase 2 OCA FLINT trial results in NASH in Lancet last week. Data from the FLINT trial highlight a comprehensive benefit, including improvement in fibrosis regardless of severity at baseline. Although relevance of lipid changes is still unclear, we believe the drug is likely to emerge as an attractive option in NASH based on overall safety/efficacy profile and absence of any approved therapy for this large patient population."

For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.

Shares of Intercept Pharmaceuticals closed at $176.35 yesterday.

You May Also Be Interested In

• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• MarineMax (HZO) PT Lowered to $35 at Stifel
• Cidara Therapeutics (CDTX) PT Raised to $25 at Needham